Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV - No Study Results Posted - ClinicalTrials.gov

Skip to Main Content

ClinicalTrials.gov

Home Search Study Topics Glossary


	Full Text View


	Tabular View


	No Study Results Posted


	Related Studies

Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV

This study has been completed.

Study NCT00006145 Information provided by National Institute of Allergy and Infectious Diseases (NIAID)

First Received: August 7, 2000 Last Updated: February 23, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Primary Completion Date:	February 2006 (Final data collection date for primary outcome measure)

Publications:

Wohl DA, Kendall MA, Andersen J, Crumpacker C, Spector SA, Feinberg J, Alston-Smith B, Owens S, Chafey S, Marco M, Maxwell S, Lurain N, Jabs D, Benson C, Keiser P, Jacobson MA; A5030 Study Team. Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030. HIV Clin Trials. 2009 May-Jun;10(3):143-52.

Back to top of Main Content